Melissa Abel
Public Communications Contact at 89BIO, INC.
Melissa Abel active positions
| Companies | Position | Start | End |
|---|---|---|---|
| 89BIO, INC. | Public Communications Contact | - | - |
Career history of Melissa Abel
Former positions of Melissa Abel
| Companies | Position | Start | End |
|---|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Corporate Officer/Principal | 31/12/2015 | 31/12/2019 |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 31/12/2015 | 31/12/2019 |
| Smithkline Beecham | Sales & Marketing | 31/12/1994 | 01/01/1999 |
Training of Melissa Abel
| Emory University | Masters Business Admin |
| The University of Chicago | Undergraduate Degree |
Statistics
International
| United States | 6 |
| Belgium | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Public Communications Contact | 1 |
| Sales & Marketing | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| 89BIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
| Smithkline Beecham | |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Technology Services |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
- Stock Market
- Insiders
- Melissa Abel
- Experience
